Sponsored Links

Symphogen Presents Preliminary Results From Phase 2 Clinical Trial With Rozrolimupab At The Annual European Hematology Association PDF Print E-mail
Medical News - Hematology
Symphogen announced preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities and shows preliminary signs of clinical and biological activity by decreasing haemoglobin values...

Read more: Blood / Hematology News From Medical News Today